Spadin
目录号 : GC13353
An inhibitor of K2P2.1/TREK1
Cas No.:1270083-24-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Spadin is a potent TREK-1 channel inhibitor with IC50 of 71nM. It is a secreted peptide derived from the propeptide generated by the maturation of NTSR3/Sortilin. [1]
TREK-1, aka KCNK2, is a two-pore domain ion channel that involved in the passive transmembrane K+ transport. It is related to the ischemia, anesthesia and electrogenesis in the neurons. It also plays an important role in the pathophysiological process of depression and in the response to antidepressant. [1]
In TREK-1 transfected COS-7 cells, 100nM of spadin inhibited 63% of the TREK-1 current stimulated by arachidnice acid. Spadin also blocked the TREK-1 channels activity in CA3 hippocampal neurons on brain slices of wild-type mice. [1]
In behavioral tests that predicting an antidepressant response, spadin-treated mice displayed a resistance to depression. Mice treated with spadin for 4 days also exhibited a significant antidepressant effect as well as elevated hippocampal phosphorylation of CREB protein and neurogenesis. [2]
References:
1. Borsotto M, Veyssiere J, Moha Ou Maati H et al. Targeting two-pore domain K(+) channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept. Br J Pharmacol. 2015 Feb;172(3):771-84.
2. Mazella J, Pétrault O, Lucas G, et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol. 2010 Apr 13;8(4):e1000355.
| Cas No. | 1270083-24-3 | SDF | |
| 化学名 | (1Z,3S,4Z,7Z,9S,10Z,12S,13Z,15S,16Z,19Z,21S,22Z,24S)-15-((1H-indol-3-yl)methyl)-1-((S)-1-((6S,7Z,9S,10Z,12S,13Z)-9-((1H-indol-3-yl)methyl)-1-amino-6-((Z)-(((S)-1-((S)-2-((Z)-(((S)-1-((S)-2-((Z)-((S)-2-amino-1-hydroxy-3-(4-hydroxyphenyl)propylidene)amino)p | ||
| Canonical SMILES | CC[C@]([C@@](/N=C(O)/[C@]1([H])CCCN1C(C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@]2([H])CCCN2C([C@](/N=C(O)/[C@]3([H])CCCN3C([C@](/N=C(O)/[C@](N)([H])CC4=CC=C(O)C=C4)([H])C)=O)([H])CC(C)C)=O)([H])CCCNC(N)=N)([H])CC5=CNC6=CC=CC=C56)([H])CO)=O)([H]) | ||
| 分子式 | C96H142N26O22 | 分子量 | 2012.32 |
| 溶解度 | Soluble to 2 mg/ml in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.4969 mL | 2.4847 mL | 4.9694 mL |
| 5 mM | 0.0994 mL | 0.4969 mL | 0.9939 mL |
| 10 mM | 0.0497 mL | 0.2485 mL | 0.4969 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet